ArticlePharmacoEconomics2019

Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer.

Min Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.